Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carfilzomib + thalidomide + dexamethasone for newly diagnosed multiple myeloma
NL-OMON46962Phase 2Active, not recruiting
- Sponsor
- Erasmus MC
- Start
- Aug 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of carfilzomib, thalidomide and dexamethasone in multiple myeloma (MM), sponsored by Erasmus MC. Primary endpoint: Response. Started Aug 2010; status: active, not recruiting.
02
Drugs
carfilzomibthalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON46962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46962.